Human CD23/Fc epsilon RII Alexa Fluor® 488-conjugated Antibody Summary
Accession # P06734
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
Background: CD23/Fc epsilon RII
CD23 (also named B cell differentiation antigen) is a member of subgroup II of the C-type (Ca++-dependent) lectin superfamily (1‑5). Human CD23 is a 47 kDa type II transmembrane glycoprotein that is expressed by a wide variety of cell types (6‑10). The full-length receptor is 321 amino acids (aa) in length and contains a 274 aa extracellular region, a 26 aa transmembrane segment, and a 21 aa cytoplasmic domain. The extracellular region contains a C-type lectin domain and a connecting stalk with coiled-coil topography (3, 11). The lectin domain binds both protein and carbohydrate in an apparently Ca++ independent manner (11). The coiled-coil region contributes to oligomerization (11, 12). The lectin domain in human CD23 (aa 162‑284) is 64%, 62% and 68% aa identical to the lectin domains in mouse, rat and bovine CD23, respectively. In the cytoplasmic region, two FC isoforms exist which arise from alternate start sites (6, 12). The “a” (or long) isoform begins with the sequence MEEGQYS and is constitutively expressed by B cells. It is believed to participate in IgE-mediated endocytosis (13). The “b” (or short) isoform begins with MNPPSQ and is induced on a wide variety of cell types by IL-4 (6). Fcb reportedly contributes to IgE-mediated phagocytosis (13). Fcb expressing cells include eosinophils, monocytes, visceral smooth muscle and intestinal epithelium (6, 14, 15). At least four soluble forms of CD23 are known to exist. They range in molecular weight from 25 kDa to 37 kDa, with the 25 kDa form predominating in sera (16). Soluble CD23 (sFc) is generated by metalloprotease (ADAM8; ADAM15; ADAM28) and cysteine-protease activity (16‑18). Cleavage usually occurs between aa 150‑160 (7, 8). It is unclear if sequential metalloprotease-cysteine protease activity is necessary for the generation of all soluble forms. Both soluble and membrane-bound CD23 show bioactivity. Ligands for CD23 include CD21, IgE, CD11b, and CD11c (19‑21). CD23 binding to CD11b and Cd11c on monocytes results in oxidative product generation and proinflammatory cytokine release (21). On B cells, sCD23 induces IgE secretion by binding CD21. Conversely, secreted IgE will, in turn, bind B cell membrane CD23, rendering it unavailable for cleavage, and thus shutting down IgE production (11).
- Kijimoto-Ochiai, S. (2002) Cell. Mol. Life Sci. 59:648.
- Heyman, B. (2000) Annu. Rev. Immunol. 18:709.
- Bajorath, J. and A. Aruffo (1996) Protein Sci. 5:240.
- Drickamer, K. (1993) Curr. Opin. Struct. Biol. 3:393.
- Drickamer, K. (1999) Curr. Opin. Struct. Biol. 9:585.
- Yokota, A. et al. (1988) Cell 55:611.
- Ludin, C. et al. (1987) EMBO J. 6:109.
- Ikuta, K. et al. (1987) Proc. Natl. Acad. Sci. USA 84:819.
- Kikutani, H. et al. (1986) Cell 47:657.
- Letellier, M. et al. (1988) J. Immunol. 141:2374.
- Hibbert, R.G. et al. (2005) J. Exp. Med. 202:751.
- Beavuil, A.J. et al. (1992) Proc. Natl. Acad. Sci. USA 89:753.
- Yokota, A. et al. (1992) Proc. Natl. Acad. Sci. USA 89:5030.
- Belleau, J.T. et al. (2005) Clin. Mol. Allergy 3:6.
- Tu, Y. et al. (2005) Gastroenterology 129:928.
- Marolewski, A.E. et al. (1998) Biochem. J. 333:573.
- Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
- Karagiannis, S.N. et al. (2001) Immunology 103:319.
- Aubry, J-P. et al. (1992) Nature 358:505.
- Sarfati, M. and G. Delespeese (1988) J. Immunol. 141:2195.
- Lecoanet-Henchoz, S. et al. (1995) Immunity 3:119.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD23/Fc epsilon RII Alexa Fluor® 488-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CD23/Fc epsilon RII Alexa Fluor® 488-conjugated Antibody and earn rewards!
Have you used Human CD23/Fc epsilon RII Alexa Fluor® 488-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image